Document is current
Any future updates will be listed below
-
Authors
Quach, Bryan C. https://orcid.org/0000-0002-1094-3104
Bray, Michael J.
Gaddis, Nathan C.
Liu, Mengzhen https://orcid.org/0000-0001-6550-6959
Palviainen, Teemu https://orcid.org/0000-0002-7847-8384
Minica, Camelia C. https://orcid.org/0000-0001-7140-8167
Zellers, Stephanie https://orcid.org/0000-0001-8927-3483
Sherva, Richard
Aliev, Fazil https://orcid.org/0000-0001-8357-4699
Nothnagel, Michael
Young, Kendra A.
Marks, Jesse A. https://orcid.org/0000-0002-8159-3594
Young, Hannah https://orcid.org/0000-0002-4248-9612
Carnes, Megan U.
Guo, Yuelong https://orcid.org/0000-0003-1287-1906
Waldrop, Alex https://orcid.org/0000-0002-4502-7894
Sey, Nancy Y. A. https://orcid.org/0000-0001-8762-7401
Landi, Maria T. https://orcid.org/0000-0003-4507-329X
McNeil, Daniel W.
Drichel, Dmitriy https://orcid.org/0000-0001-5978-3458
Farrer, Lindsay A.
Markunas, Christina A.
Vink, Jacqueline M.
Hottenga, Jouke-Jan https://orcid.org/0000-0002-5668-2368
Iacono, William G.
Kranzler, Henry R. https://orcid.org/0000-0002-1018-0450
Saccone, Nancy L. https://orcid.org/0000-0002-4710-3926
Neale, Michael C.
Madden, Pamela
Rietschel, Marcella https://orcid.org/0000-0002-5236-6149
Marazita, Mary L. https://orcid.org/0000-0002-2648-2832
McGue, Matthew
Won, Hyejung https://orcid.org/0000-0003-3651-0566
Winterer, Georg
Grucza, Richard
Dick, Danielle M. https://orcid.org/0000-0002-1636-893X
Gelernter, Joel https://orcid.org/0000-0002-4067-1859
Caporaso, Neil E.
Baker, Timothy B.
Boomsma, Dorret I. https://orcid.org/0000-0002-7099-7972
Kaprio, Jaakko https://orcid.org/0000-0002-3716-2455
Hokanson, John E.
Vrieze, Scott https://orcid.org/0000-0003-3861-7930
Bierut, Laura J. https://orcid.org/0000-0002-9952-4810
Johnson, Eric O. https://orcid.org/0000-0002-8870-1949
Hancock, Dana B. https://orcid.org/0000-0003-2240-3604
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01DA042090)
- License Information
-
More Information
Article History
Received: 21 January 2020
Accepted: 24 September 2020
First Online: 3 November 2020
Competing interests
: L.J.B. and the spouse of N.L.S. are listed as inventors on U.S. Patent 8,080,371, ‘Markers for Addiction’ covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. Y.G. is an employee of GeneCentric Therapeutics. Although unrelated to this research, H.R.K. is an advisory board member for Dicerna and a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last 3 years by AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor and Amygdala Neurosciences. H.R.K. and J.G. are named as inventors on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. J.K. consulted for Pfizer in 2012–2015 on ND. The remaining authors declare no competing interests.
